Stocks and Investing Stocks and Investing
Tue, November 8, 2022

Luca Issi Maintained (VERV) at Buy with Decreased Target to $35 on, Nov 8th, 2022


Published on 2024-10-28 00:01:13 - WOPRAI, Luca Issi
  Print publication without navigation


Luca Issi of RBC Capital, Maintained "Verve Therapeutics, Inc." (VERV) at Buy with Decreased Target from $42 to $35 on, Nov 8th, 2022.

Luca has made no other calls on VERV in the last 4 months.



There are 3 other peers that have a rating on VERV. Out of the 3 peers that are also analyzing VERV, 1 agrees with Luca's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Richard Law of "Credit Suisse" Initiated at Hold and Held Target at $48 on, Thursday, October 6th, 2022


These are the ratings of the 2 analyists that currently disagree with Luca


  • Dae Gon Ha of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $56 on, Thursday, August 25th, 2022
  • Kostas Biliouris of "BMO Capital" Maintained at Buy with Increased Target to $62 on, Monday, July 18th, 2022
Contributing Sources